ArticleDiscover oncology2025
Cell division cycle 25 C (CDC25C) mediates cell-cycle progression and immune evasion in glioma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Decoding the Prognosis-Related S100A9OncoTargets and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundGliomas are highly aggressive brain tumors with poor outcomes. CDC25C, a phosphatase that activates the CDK1-Cyclin B1 complex at the G₂/M checkpoint, is implicated in several cancers but its role in glioma progression and tumor immunity remains unclear.
methodsWe integrated bulk transcriptomic datasets (TCGA, CGGA, GEO) and single-cell RNA sequencing data to evaluate CDC25C expression, prognostic significance, and associated pathways in gliomas. Immune cell infiltration and checkpoint gene correlations were assessed via computational deconvolution. Additionally, U87MG glioma cells were transfected with siRNAs targeting CDC25C to achieve transient knockdown. Proliferation was measured by EdU incorporation, cell-cycle distribution by flow cytometry, and expression of G₂/M regulators (Cyclin B1, CDK1, phospho-CDK1) by Western blot.
resultsCDC25C was overexpressed in gliomas compared to normal brain, and high CDC25C levels correlated with advanced tumor grade, other poor prognostic markers, and shorter overall survival. Gene set analyses revealed CDC25C-high tumors were enriched in cell-cycle and immunosuppressive pathways. High CDC25C expression was associated with greater infiltration of regulatory T cells (Tregs) and M0 macrophages, alongside upregulation of immune checkpoints PD-1, PD-L1, and CD80. Single-cell RNA-seq localized CDC25C-driven proliferation to a hyperproliferative MKI67-positive tumor cell subpopulation. Functionally, CDC25C knockdown in U87MG cells suppressed proliferation, induced G₂/M arrest, and inhibited the CDK1-Cyclin B1 mitotic axis.
conclusionsCDC25C is a critical driver of glioma cell proliferation and an enabler of immune evasion. Its overexpression may link unchecked mitotic progression with an immunosuppressive microenvironment, underscoring CDC25C as a promising prognostic biomarker and therapeutic target in glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.